By Drug Target Review2025-12-12T09:00:13
RNA therapies are moving past burst-and-fade limits. New advances in circular RNA and targeted delivery could transform how we treat autoimmune disease, infections and beyond.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2024-02-07T14:34:33
Sponsored by BellBrook Labs
2025-04-02T14:00:00
Sponsored by Eurofins Discovery
2024-05-07T13:11:19
Sponsored by BellBrook Labs
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2024-01-19T07:40:55
Sponsored by Euretos
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
Site powered by Webvision Cloud